Trials / Completed
CompletedNCT04011735
Re-usable Respimat® Soft MistTM Inhaler Study
A Real-world Non-interventional Study to Assess Patient Satisfaction With and Preference for Re-usable Respimat Soft Mist Inhaler in Patients With Chronic Obstructive Pulmonary Disease.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 262 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Respimat | Soft Mist Inhaler product |
Timeline
- Start date
- 2019-09-30
- Primary completion
- 2020-02-13
- Completion
- 2020-02-13
- First posted
- 2019-07-08
- Last updated
- 2021-03-03
- Results posted
- 2021-03-03
Locations
20 sites across 6 countries: Belgium, Denmark, Finland, Germany, Netherlands, Norway
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04011735. Inclusion in this directory is not an endorsement.